Investor Presentaiton

Strategic Vision Well Diversified Pharma Company Novel products Integrated Global Quality Culture North America Women's Health NaMuscla Franchise Committed to building robust specialty business Complex Generics Investing heavily in the development of high barrier therapeutics Capability building and portfolio expansion Global Inhalation Platform Execution and scaling in our markets and beyond Geographic expansion and partnership Novel Oncology Research Platform Pipeline acceleration Global Biosimilars Business Launch execution, Portfolio expansion and Development Global Long Acting and US Gx Injectables Clinical execution and Scale Strong Generics Foundation Amongst the Top 10 generic companies in the World US Generics Growth driven by a diversified portfolio Execution on high-value opportunities India Region Formulations Achieving Top 3 by share Build select adjacencies Other Growth Markets Self Sustenance, Growth and Operating Leverage Commercial leverage through In-licensing, M&A and Partnerships Highly scaled and efficient Research, Development and Operational capabilities LUPIN 04

View entire presentation